Pharma Licensing – an introduction

23/11/2022
Reports
Michelle Thomas

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process.

We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch!

Click to read Pharma licensing – an introduction


>>>Pharma Licensing: the why the how and a few things to get right

Results Healthcare has recently advised Servier on the out-licensing of the global rights to the Sym022 programme, an anti-LAG3 monoclonal antibody.

Our specialist healthcare team, with backgrounds in the life sciences, understand the complexities of valuations and deal structures that are unique to licensing deals in pharma and biotech and are with our clients every step of the way.

We support clients with:

– In-licensing
– Out-licensing
– Co-development
– Co-commercialisation